Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digene to develop DNA test for herpes:

This article was originally published in Clinica

Executive Summary

Digene has received a grant from the US National Institutes of Health to develop a DNA test for the herpes simplex virus (HSV) based on the company's Hybrid Capture II technology. The company plans to use the $750,000 award to develop a simple, sensitive and cost-effective test to improve detection, screening and monitoring of patients with HSV Types 1 and 2 infection. The Beltsville, Maryland-based company estimated that three to five million HSV tests are performed annually in the US, while six to 10 million are carried out worldwide.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT081651

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel